Two medical oncologists summarize data on use of circulating tumor DNA as a predictive biomarker in solid tumor patients treated with pembrolizumab.
Personalized Circulating Tumor DNA Analysis as a Predictive Biomarker in Solid Tumors
George Ansstas, MD, and Firas B. Badin, MD, discuss the potential clinical implications of using circulating tumor DNA as a predictive biomarker in solid tumor patients treated with immunotherapy.
CancerNetwork® recaps a Between the Lines journal club program with George Ansstas, MD, and Firas B. Badin, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
ASH 2025: Which Presentations Will Move the Multiple Myeloma Needle?
2
ASH 2025: Key Anticipated Updates in the Leukemia Landscape
3
FDA Approves Liso-Cel in Marginal Zone Lymphoma After 2 Lines of Therapy
4
FDA and EMA Clear Phase 3 POLARIS-1 Trial in Newly Diagnosed Ph+ ALL
5
